coronavirus
cov
envelop
rna
virus
caus
respiratori
enter
diseas
cov
wide
distribut
natur
zoonot
transmiss
human
popul
caus
epidem
diseas
enter
respiratori
gastrointestin
tract
virus
establish
enter
infect
lumen
macrophag
epitheli
cell
cell
entri
program
virus
orchestr
viral
spike
protein
bind
cellular
receptor
also
mediat
viruscel
membran
fusion
cov
divers
reflect
variabl
protein
evolv
form
differ
receptor
interact
respons
variou
environment
trigger
viruscel
membran
fusion
seemingli
minor
differ
cov
protein
structur
function
often
correl
strike
chang
cov
tropism
virul
review
focus
receptor
interact
event
lead
membran
fusion
success
cell
entri
protein
larg
averag
cov
protein
contain
amino
acid
asparaginelink
glycan
make
protein
substanti
larger
glycoprotein
mediat
receptor
bind
membran
fusion
envelop
virus
monom
assembl
trimer
within
er
virusproduc
cell
incorpor
viru
particl
cov
bud
site
near
ergolgi
intermedi
compart
human
sever
acut
respiratori
syndrom
sar
cov
mous
hepat
viru
mhv
cov
virionassoci
protein
imag
angstrom
resolut
cryoelectron
microscopi
trimer
sarscov
mhv
particl
trimer
held
onto
virus
transmembran
anchor
locat
near
ctermini
vast
major
protein
mass
extravirion
locat
protrud
nm
limit
viru
membran
nmdiamet
particl
figur
structur
known
domain
compris
sar
mhv
protein
includ
receptor
bind
domain
rbd
part
ntermin
half
primari
sequenc
figur
rbd
structur
complex
cognat
cell
receptor
figur
provid
sever
insight
initi
viruscel
interact
atomicallyresolv
structur
amount
small
portion
ctermin
half
primari
sequenc
figur
reveal
coiledcoil
made
three
alpha
helic
term
heptad
repeat
hr
along
three
chain
term
bound
onto
outer
surfac
coil
coil
figur
note
singl
heterom
clarif
complex
three
three
term
sixhelix
bundl
stabl
proteaseresist
structur
part
protein
denatur
catalyz
membran
fusion
postfus
form
structur
nativ
prefus
conform
known
furthermor
atom
structur
remain
protein
known
protein
conform
model
depict
smediat
membran
fusion
event
extend
knowledg
protein
structur
function
part
model
deem
reason
postfus
conform
sar
mhv
protein
strikingli
similar
postfus
form
influenza
paramyxoviru
ebolaviru
hiv
analog
widelystudi
wellunderstood
viral
fusion
protein
cov
smediat
membran
fusion
process
gener
view
schemat
figur
follow
receptor
bind
cov
protein
undergo
conform
chang
expos
hydrophob
domain
like
includ
socal
fusion
peptid
fp
emb
target
cell
membran
primari
sequenc
data
along
measur
fusion
activ
sitedirect
mutant
suggest
fp
near
immedi
ntermin
see
figur
propos
fp
locat
stage
fp
target
cell
membran
transmembran
tm
span
virion
membran
protein
consid
fusion
intermedi
conform
follow
refold
region
fp
tm
span
postfus
configur
like
multistep
process
bring
oppos
membran
suffici
proxim
lipid
mix
ultim
coalesc
addit
fp
tm
span
structur
element
particip
later
step
includ
hydrophob
tryptophanrich
region
boundari
tm
span
ectodomain
posttransl
palmitoyl
region
boundari
tm
span
cytoplasm
domain
complet
membran
fusion
fp
tm
hypothes
adjac
extend
end
membran
bilay
clear
analog
major
virus
promot
membran
fusion
way
peptid
bind
region
fusion
intermedi
conform
potent
block
cov
cell
entri
membran
fusion
stage
like
prevent
complet
latestag
refold
understand
cov
entri
provid
sophist
basi
continu
explor
cov
incent
continu
research
cov
entri
proven
cov
zoonot
potenti
extraordinari
pathogen
human
knowledg
base
cov
entri
offer
potenti
save
live
signific
gap
knowledg
base
current
incent
understand
virusreceptor
interact
protein
trigger
catalyz
membran
fusion
ad
knowledg
base
cov
model
system
also
bring
new
insight
gener
relev
viru
entri
membran
fusion
review
cover
recent
progress
ad
fund
knowledg
cov
entri
section
review
organ
accord
event
cov
infect
cycl
begin
biogenesi
secret
viru
particl
start
point
chosen
highlight
protein
matur
event
virusproduc
cell
emphas
continu
prepar
membran
fusion
take
place
virusproduc
virustarget
cell
subsequ
section
proceed
virusreceptor
interact
role
induc
protein
conform
chang
next
import
endocytosi
discuss
proteolyt
scission
cell
surfac
within
endosom
underscor
critic
featur
cov
cell
entri
event
readi
virus
cell
entri
begin
virusproduc
cell
cov
begin
stage
endoplasm
reticulum
virusproduc
cell
protein
synthes
assembl
trimer
erloc
assembl
trimer
slow
process
take
approxim
min
gener
greater
glycoprotein
complex
nascent
trimer
transit
exocyt
pathway
embed
ctermin
transmembran
domain
vesicl
membran
virion
membran
incorpor
virus
viru
bud
site
ultim
resid
plasma
membran
secret
virion
conceiv
cov
infect
process
establish
novel
exocyt
rout
perhap
distend
organel
abl
accommod
secret
larg
cov
virion
cargo
exocyt
vesicl
may
even
alter
virion
protein
hous
preserv
properli
rout
cell
note
cov
e
protein
small
oligomer
transmembran
peptid
accumul
ergolgi
intermedi
compart
membran
possess
ion
channel
activ
may
gener
role
corrupt
secretori
organel
virion
expel
infecti
form
virusproduc
cell
protein
cov
undergo
earli
proteolysi
event
figur
transgolgi
network
hous
acid
phactiv
serin
proteas
notabl
furin
cleav
protein
posit
immedi
ctermin
multibas
cleavag
site
place
label
cleavag
site
figur
scission
also
design
cleavag
separ
rbd
fusion
machineri
noncovalentlyassoci
peripher
transmembraneanchor
fragment
furin
proprotein
convertas
respons
proteas
establish
use
peptid
furin
inhibitor
arrest
cleavag
notabl
subset
cov
protein
multibas
cleavag
site
select
consensu
krxkrkr
motif
posit
thu
cov
infect
protein
popul
left
intact
partial
cleav
virusproduc
cell
protein
harbor
cleavag
site
motif
sitedirect
mutat
multibas
residu
render
uncleav
state
destroy
viru
infect
experi
involv
pharmacolog
inhibit
furin
complement
evalu
mutant
virus
reveal
reduc
furin
activ
greatli
reduc
cleavag
without
diminish
viru
infect
cleavag
howev
increas
potenc
cov
protein
mediat
cellcel
fusion
influenc
syncyti
develop
may
explain
evolutionari
divers
cleavag
syncytia
may
benefit
cov
certain
nich
ie
acut
infect
promot
rapid
viru
dissemin
provir
effect
may
select
multibas
cleavag
motif
nich
ie
chronic
smolder
infect
weaken
syncyti
cell
may
greatli
compromis
virusproduc
capac
antivir
effect
may
select
multibas
peptid
sequenc
addit
entir
distinct
select
forc
may
target
basic
peptid
motif
krxkrkr
stretch
mediat
viru
bind
heparan
sulfat
known
receptor
murin
cov
adsorpt
heparan
sulfat
provir
tissu
cultur
antivir
vivo
make
complex
select
forc
imping
multibas
peptid
motif
exactli
cleavag
promot
syncytia
cellcel
fusion
often
without
signific
effect
viru
entri
viruscel
fusion
yet
entir
clear
notabl
cleavag
site
distant
hydrophob
peptid
hundr
residu
presum
fusion
peptid
figur
posit
clearli
unlik
analog
cleavag
site
influenza
hemagglutinin
hiv
adjac
fusion
peptid
thu
creat
hydrophob
ntermini
target
membran
insert
simpl
model
cleavag
liber
ntermin
fusion
peptid
appear
unsatisfactori
hypothes
addit
cleavag
nearer
fusion
peptid
support
hypothesi
preproprotein
place
cleavag
final
fusionact
like
take
place
later
time
continuum
viru
assembl
secret
entri
new
cell
describ
detail
follow
section
cov
regardless
preprim
protein
cleavag
statu
initi
new
infect
bind
receptor
virustarget
cell
receptorbind
event
variabl
amongst
cov
potenti
prime
subsequ
virustarget
cell
membran
fusion
discuss
fascin
featur
cov
divers
receptorbind
event
divers
show
readili
upon
inspect
cov
receptor
includ
integralmembran
protein
sugar
group
obviou
structur
similar
tabl
variat
present
interest
question
regard
receptor
simpli
mediat
cov
adsorpt
might
ie
gener
fusionpromot
protein
conform
chang
andor
direct
virus
particular
endocyt
rout
sever
studi
demonstr
cov
receptor
may
requir
special
endocyt
function
beyond
bind
integralmembran
protein
receptor
lack
cytoplasm
tail
thu
unlik
regul
viru
endocytosi
transduc
viruspromot
signal
still
provid
viru
entri
case
mhvcov
ceacam
receptor
tabl
cell
entri
catalyz
solubl
exogenouslyad
ceacam
ectodomain
indic
receptor
advanc
entri
bind
role
receptor
guid
bound
virus
particular
endocyt
organel
absolut
essenti
divers
receptor
interact
also
readili
evid
examin
cov
protein
protein
strike
group
possess
least
two
rbd
one
rbd
encompass
ntermin
domain
ntermin
rbd
figur
tabl
recent
structur
resolut
ntd
mhvcov
reveal
galectinlik
betasandwich
fold
inde
ntd
relat
cov
strain
human
bovin
cov
function
lectin
bind
variou
acetyl
sialic
acid
remark
resolv
mhv
ntd
structur
lack
peptid
loop
necessari
sugar
bind
thu
oper
lectin
instead
possess
high
affin
ceacam
protein
intrigu
indic
ntermin
rbd
structur
evolv
dispar
sugar
protein
receptorbind
activ
find
valuabl
consid
cov
receptor
switch
relat
host
rang
zoonot
infect
potenti
cov
rbd
encompass
region
near
middl
term
ctermin
domain
ctd
ctermin
rbd
structur
human
sar
shown
figur
shown
cov
complet
distinct
beta
sheet
architectur
sar
beta
sandwich
yet
two
ctd
rbd
bind
region
within
receptor
term
viru
bind
hotspot
sar
ctd
welldescrib
mutat
chang
affin
human
civet
cat
bat
receptor
expect
viru
affin
human
correl
human
infect
epidem
human
human
transmiss
ctd
structur
cov
bind
apn
yet
undetermin
receptor
yet
avail
determin
may
foster
analog
identif
mutat
chang
affin
far
divers
receptor
studi
promot
understand
cov
ctermin
rbd
like
ntermin
rbd
possess
flexibl
architectur
evolv
dispar
receptorbind
activ
contribut
acquisit
new
host
rang
zoonos
notabl
exist
two
cov
rbd
make
one
dispens
mhv
ceacambind
site
ntd
readili
delet
ctd
segment
passag
tissu
cultur
deletionmut
profound
influenc
cov
virul
greatli
decreas
murin
viru
neurovirul
anoth
interest
exampl
porcin
cov
transmiss
gastroenter
viru
tgev
two
function
rbd
tabl
infect
respiratori
enter
tract
howev
naturallyoccur
mutant
substitut
delet
ntermin
rbd
lack
lectin
activ
strictli
limit
respiratori
tract
therefor
attenu
thu
dual
rbd
architectur
may
correl
vivo
tropism
virul
like
due
complex
multipl
receptor
interact
cov
employ
natur
anim
environ
divers
receptor
interact
preced
cov
smediat
fusion
reaction
bind
rel
lowaffin
carbohydr
receptor
may
gener
fusionpromot
protein
conform
protein
receptor
bind
protein
high
affin
clearli
evidenc
extens
studi
mhv
earli
semin
find
use
mhv
demonstr
alkalin
ph
increas
fusion
activ
releas
readili
observ
conform
chang
solubl
ceacam
receptor
found
catalyz
releas
biolog
relev
subsequ
establish
solubl
receptor
found
support
infecti
mhv
entri
ceacamneg
cell
recent
use
strain
solubl
ceacam
receptor
gener
sdsresist
protein
trimer
uniqu
lipophil
proteas
suscept
thu
mhv
model
system
divulg
rel
stabl
ceacam
receptorinduc
conform
quit
like
intermedi
structur
way
membran
fusion
see
figur
hypothet
illustr
receptorinduc
gener
fusion
intermedi
structur
disclos
mhv
model
system
howev
ceacam
bind
ntd
rbd
uncov
fusion
machineri
primari
sequenc
ntd
rbd
distant
fusioninduc
peptid
structur
biologist
undoubtedli
address
issu
effect
present
intrigu
molecular
genet
data
strongli
suggest
connect
rbd
fusion
apparati
context
nativ
trimer
one
first
find
support
connect
identif
mutat
fusion
domain
destroy
antibodi
epitop
rbd
numer
compar
observ
sinc
inde
mhv
evolut
vitro
vivo
frequent
fix
substitut
mutat
near
rbd
fusion
region
sever
instanc
mutat
chang
rbd
affin
ceacam
increas
decreas
tendenc
protein
undergo
ceacaminduc
transit
fusionintermedi
form
suggest
one
select
pressur
relat
mhv
respons
ceacam
receptor
trigger
final
fact
mutat
frequent
associ
reduc
viru
virul
creat
addit
suggest
complet
understand
cov
diseas
requir
appreci
receptor
oper
fusion
trigger
rel
ceacam
effect
mhv
role
apn
receptor
trigger
structur
transit
human
cov
less
clear
exampl
uncertain
whether
bind
sar
protein
dissoci
rbd
fusion
modul
expos
hydrophob
fusion
peptid
compel
data
howev
suggest
protein
set
proteolyt
scission
activ
membran
fusion
describ
follow
section
human
cov
receptor
therefor
may
similar
murin
ceacam
cov
receptor
bind
energi
drive
protein
intermedi
form
expos
proteolyt
substrat
site
host
proteas
may
ultim
liber
fusion
machineri
allow
oper
cov
entri
final
question
whether
viru
entri
receptorinduc
conform
chang
lead
membran
fusion
take
place
plasma
membran
later
time
virus
enter
endosom
question
explor
follow
section
endocytosi
princip
cell
entri
rout
virus
receptormedi
endocytosi
advantag
entri
rout
allow
viru
endosom
pass
barrier
cortic
actin
traffic
deepli
cell
fuse
expel
genom
cytosol
endosom
also
bath
viru
acid
proteolyt
environ
frequent
necessari
activ
viral
fusion
appear
major
cov
enter
cell
via
endocytosi
howev
subset
cov
thought
enter
straightforward
direct
fusion
plasma
membran
make
cov
use
dissect
variou
cell
entri
rout
idea
cov
endocytos
rather
enter
fusion
directli
plasma
membran
come
sever
find
includ
fact
sever
cov
readili
induc
syncytia
ie
plasma
membraneloc
cellcel
fusion
studi
ph
effect
investig
syncyti
develop
increas
slightli
alkalin
media
suggest
need
endosom
acid
exposur
activ
fusion
similarli
cov
notabl
jhm
strain
mhv
impervi
inhibitor
endosom
acidif
final
incub
receptorbear
cell
extraordinarili
high
input
multipl
cov
induc
immedi
cellcel
fusion
often
call
fusionfromwithout
none
observ
necessarili
confirm
cov
natur
enter
cell
via
fusion
plasma
membran
first
may
inappropri
equat
syncyti
format
cellcel
fusion
viru
entri
viruscel
fusion
two
process
distinct
requir
reveal
mutat
abolish
syncyti
format
without
affect
viru
infect
discuss
later
review
second
increas
syncyti
activ
basic
ph
may
reflect
ph
optima
cellsurfac
trypsinlik
proteas
creat
fusionact
fragment
may
primarili
appli
fusion
mediat
protein
associ
virion
third
resist
cov
endosom
neutral
indic
fusion
earli
nonacid
endosom
use
conclud
viruscel
fusion
take
place
plasma
membran
inde
sever
report
particularli
hiv
research
virus
acquir
membran
fusion
compet
neutral
ph
may
still
util
endosom
network
entri
leav
fusion
without
phenomena
clearli
plasma
membranebas
viruscel
fusion
event
perhap
occur
low
frequenc
thu
observ
artifici
experiment
condit
virus
appli
cell
extrem
high
dose
cov
gener
util
cellular
endocyt
machineri
entri
also
support
studi
aim
dissect
cov
entri
pathway
mani
investig
assess
effici
cov
infect
specif
arrest
clathrin
caveolar
cholesteroldepend
endocytosi
pharmacolog
agent
overexpress
dominantneg
protein
valuabl
result
indic
variou
cov
entri
pathway
caveolar
endocytosi
human
clathrinmedi
endocytosi
sarscov
cholesterolraft
entri
mhv
clathrin
endocytosi
felin
cov
howev
complet
blockad
cov
entri
rare
achiev
suppress
singl
endocyt
pathway
suggest
multipl
cell
entri
rout
util
cov
cov
resourc
invad
cell
altern
rout
exemplifi
success
sarscov
entri
clathrin
caveolar
endocytosi
block
similarli
sarscov
entri
receptormedi
process
typic
traffic
virus
acid
organel
entir
distinct
mediat
antibodi
fcgammareceptor
ii
socal
antibodydepend
enhanc
entri
infect
entir
unaffect
endosom
neutral
agent
proteas
inhibitor
arrest
entri
process
summari
differ
cov
endocyt
entri
rout
culmin
success
infect
endosom
cov
bath
acid
often
proteolyt
environ
protein
major
cov
strain
clearli
requir
acid
exposur
acquir
membran
fusion
compet
howev
unclear
whether
proton
endosom
factor
trigger
fusion
per
se
acidif
enhanc
smediat
fusion
acid
phactiv
endosom
proteas
may
like
trigger
henc
interest
question
aris
whether
entri
depend
acid
endosom
condit
sole
fusionactiv
proteas
acid
phdepend
question
consid
studi
filoviru
entri
cov
present
addit
studi
model
effect
proton
cov
fusion
structur
dynam
evalu
magnet
reson
cov
model
system
appear
pois
contribut
gener
understand
protontrigg
viru
entri
initi
obviou
proteolysi
take
place
virusproduc
cell
posit
figur
gener
secret
virus
peripher
transmembran
fragment
event
figur
state
previou
section
morphogenesi
scission
observ
cov
cov
uncleav
protein
relev
scission
take
place
viru
entri
event
figur
simmon
et
al
matsuyama
et
al
made
initi
semin
discoveri
cathepsin
l
inhibitor
block
sar
mediat
viru
entri
trypsin
proteolysi
bypass
inhibit
make
clear
cell
entri
via
sar
protein
depend
proteolyt
cleavag
cathepsin
l
enlighten
result
aros
nearli
concurr
discoveri
ebolaviru
entri
requir
cathepsin
cleavag
fusion
glycoprotein
thu
establish
endosom
proteas
promot
entri
differ
envelop
virus
subsequ
question
regard
cleavag
address
biochem
found
sar
ectodomain
cleav
cathepsin
l
posit
figur
made
appear
depend
cov
strain
cleavag
either
take
place
earli
infect
cycl
furinlik
serin
proteas
transgolgi
network
virusproduc
cell
later
cycl
cathepsin
l
cystein
proteas
endosom
virustarget
cell
similar
ultim
outcom
support
view
precleav
sar
insert
consensu
furin
cleavag
site
freed
viru
depend
endosom
acidif
recent
find
howev
ad
complex
proteolyt
cleavag
addit
mutibas
peptid
motif
posit
design
figur
recogn
infecti
bronchiti
cov
ibv
shown
via
mutagenesi
essenti
ibv
cell
entri
homolog
posit
sar
also
found
highli
relev
mutat
consensu
furin
cleavag
motif
allow
sar
entri
without
need
exogen
trypsin
proteas
second
cleavag
site
sinc
biochem
confirm
via
identif
shorter
ctermin
fragment
sar
protein
mhv
protein
although
research
proteolyt
cascad
ongo
present
find
consist
model
protein
cleav
multipli
like
first
posit
posit
adjac
fp
gener
fusion
intermedi
structur
type
depict
figur
proteolyt
remov
sequenc
ntermin
fp
may
permit
rapid
complet
refold
event
gener
membran
fusion
configur
also
question
precis
protein
avail
proteolysi
weight
current
evid
argu
target
cell
free
extracellular
space
site
proteolysi
exampl
cellfre
sarscov
virion
render
noninfecti
trypsin
pretreat
free
virion
howev
trypsin
exposur
enhanc
infect
cellbound
virus
event
figur
find
suggest
cell
receptorassoci
protein
uniqu
proteaserespons
structur
form
experi
use
proteas
encount
incom
respiratori
cov
sarscov
find
still
impli
conform
chang
significantli
upon
receptor
interact
endocytosi
turn
illumin
import
conform
subcellular
locat
effect
proteolysi
exogen
ad
trypsin
could
increas
infect
cell
receptorassoci
sarscov
suggest
cellbound
ectoproteas
might
natur
cofactor
cov
entri
inde
cov
prime
fusion
recent
describ
cellsurfac
proteas
known
type
ii
transmembran
serin
proteas
ttsp
ttsp
may
resid
plasma
membran
microdomain
although
possibl
yet
valid
may
avail
incom
virus
receptorinteract
stage
cleav
andor
posit
prototyp
ttsp
enteropeptidas
discov
nearli
centuri
ago
recent
decad
research
reveal
least
addit
famili
member
famili
member
variat
domain
ctermin
proteas
ntermin
transmembran
anchor
role
domain
viral
glycoprotein
cleavag
unknown
may
dictat
substrat
specif
influenc
proteas
subcellular
local
associ
membran
protein
subset
ttsp
evalu
mediat
viru
entri
princip
amongst
evalu
ttsp
transmembran
proteas
serin
first
describ
role
normal
physiolog
remain
elus
larg
knockout
mice
develop
normal
may
fundament
organismwid
role
express
tissu
heart
liver
prostat
intestin
notabl
lung
abund
lung
prompt
screen
respiratori
virus
activ
glycoprotein
cleav
hemagglutinin
influenza
virus
lead
increas
replic
includ
highli
pathogen
strain
also
cleav
membran
glycoprotein
sarscov
matsuyama
et
al
discov
increas
level
result
cell
death
increas
sarscov
viral
replic
vitro
shulla
et
al
confirm
expand
find
note
specif
increas
sarscov
entri
use
pseudotyp
report
assay
cleavag
may
also
contribut
immun
evas
cleav
infectedcel
surfac
releas
fragment
bind
incapacit
neutral
antibodi
henc
vivo
infect
process
may
heavili
influenc
relat
famili
member
viru
entri
releas
influenc
pathogenesi
immun
respons
anoth
ttsp
human
airway
trypsinlik
proteas
hat
brought
enlighten
detail
concern
memberspecif
proteolyt
properti
context
influenza
ha
cleavag
hat
broader
cleavag
capac
proteolyz
ha
virusproduc
cell
progeni
virus
bound
target
cell
receptor
thu
hat
relev
proteas
oper
influenza
viru
entri
stage
context
sarscov
cleavag
hat
exhibit
broader
cleavag
capac
make
hat
cleav
enhanc
smediat
viru
entri
either
virusproduc
cell
surfac
virustarget
cell
howev
overexpress
bypass
requir
endosom
acidif
therefor
cathepsin
activ
hat
similarli
replac
cathepsin
sarscov
entri
thu
dissect
variou
ttsp
substrat
specif
necessari
precis
identifi
relev
viru
infect
effort
regard
continu
exampl
first
paper
examin
ttsp
context
sar
entri
found
capabl
slightli
enhanc
sar
bear
pseudoparticl
subsequ
find
indic
capabl
modestli
increas
sar
entri
low
level
proteas
potent
activ
entri
recent
variou
ttsp
includ
hepsin
evalu
yet
none
exceed
augment
sarscov
entri
candid
ttsp
worth
test
sarscov
entri
assay
mspl
found
cleav
certain
influenza
ttsp
may
relev
proteas
natur
cov
infect
clearli
dispens
sever
tissu
cultur
set
cathepsin
specif
cathepsin
l
proteolyt
activ
sar
cov
protein
follow
viru
endocytosi
event
figur
multipl
proteas
possibl
redund
viru
entri
function
make
difficult
discern
proteas
necessari
viral
entri
difficulti
perhap
recogn
fact
presum
proteolyt
activ
anoth
human
cov
entir
unclear
smediat
entri
affect
prevent
endosom
acidif
cathepsin
inhibitor
similar
sar
bind
receptor
proteas
respons
cleavag
remain
mysteri
current
vaccin
best
clinic
approach
erad
virus
experiment
sarscov
vaccin
immunogen
includ
inactiv
whole
virus
entir
trimer
rbd
review
formul
elicit
protect
antibodi
prevent
viru
entri
protect
lethal
sarscov
challeng
antibodi
oper
steric
block
virusreceptor
engag
howev
protect
antibodi
oper
variabl
novel
way
shown
human
monoclon
antibodi
direct
trypsin
cleavag
site
reduc
viral
titer
patholog
associ
sarscov
infect
interestingli
despit
bind
proteolyt
substrat
site
antibodi
prevent
cleavag
rather
prevent
membran
fusion
unknown
mechan
antibodi
creat
transgen
mice
produc
human
immunoglobulin
repres
interest
new
product
method
passiv
human
immun
new
approach
signal
subunit
vaccin
therapeut
antibodi
attract
futur
clinic
option
method
must
evalu
cautious
antisar
antibodi
permit
viru
entri
via
receptor
bypass
entri
rout
actual
enhanc
diseas
attract
naturalproduct
anticov
agent
includ
lectin
bind
avidli
unprocess
highmannos
carbohydr
cov
protein
one
lectin
griffithsin
oligom
six
highaffin
mannos
bind
site
griffithsin
known
block
hiv
infect
via
envelop
protein
bind
griffithsin
found
analog
antisar
activ
prevent
sarscov
infect
patholog
vitro
mous
diseas
model
without
incident
cytotox
potenti
antihuman
cov
lectin
includ
mannosebind
lectin
arrest
sarscov
entri
plant
lectin
galanthu
nivali
agglutinin
hippeastrum
hybrid
agglutinin
urtica
dioica
agglutinin
date
evalu
antimhv
activ
notabl
lectin
affect
bind
receptor
rather
seem
inhibit
entri
later
stage
sever
proteas
describ
paper
potenti
antivir
therapeut
target
inde
furininhibit
peptid
arrest
cellcel
fusion
mediat
coronavirus
mhv
ibv
infecti
bronchiti
viru
novel
druglik
cathepsin
l
inhibitor
identifi
highthroughput
screen
prevent
ebola
sarscov
cell
entri
ttsp
also
promis
antivir
drug
target
proteolyt
activ
site
expos
extracellular
milieu
hydrophil
inhibitor
remain
exclud
cell
may
suitabl
thu
reduc
medicin
chemistri
toxic
problem
transient
pharmacolog
suppress
may
health
consequ
given
mous
phenotyp
normal
target
cellular
proteas
furin
cathepsin
may
unintend
toxic
side
effect
due
import
normal
physiolog
final
target
host
protein
sensibl
adjunct
design
inhibitor
target
toward
highlymut
viru
protein
target
addit
prevent
cov
entri
inhibit
ttsp
proteas
would
also
prevent
matur
viral
glycoprotein
block
entri
varieti
virus
exampl
potenti
multi
panvir
proteas
inhibitor
human
cathepsin
l
inihibitor
tetrahydroquinolin
oxocarbaz
block
sar
ebola
glycoprotein
mediat
entri
vitro
anim
studi
yet
publish
cathepsin
inhibitor
bahgat
et
al
recent
report
cocktail
serin
proteas
inhibitor
reduc
influenza
infect
subsequ
diseas
mice
addit
histor
report
use
singl
agent
serin
proteas
inhibitor
camostat
leupeptin
aprotinin
decreas
influenza
infect
mice
human
zihnov
et
al
report
aerosol
deliveri
aprotinin
shorten
influenza
symptomatolog
human
possibl
antivir
aprotinin
target
given
abund
lung
aprotinin
penetr
plasma
membran
support
possibl
knockdown
peptideconjug
morpholino
oligom
stabl
antisens
oligonucleotid
render
posit
human
airway
cell
resist
influenza
viru
replic
end
inhibit
human
cov
may
requir
multitarget
approach
block
multipl
proteas
along
entri
pathway
might
combin
lectin
also
peptidebas
fusion
inhibitor
fusion
viral
membran
target
cell
membran
arrest
peptid
mimick
heptad
repeat
region
bind
inactiv
fusion
intermedi
form
mention
earlier
review
differ
peptid
investig
nanomolar
micromolar
rang
high
affin
specif
similar
hiv
peptid
enfuvirtid
current
use
human
refin
peptid
develop
peptidomimet
might
enhanc
antivir
activ
make
even
suitabl
anticov
treatment
peptid
cover
broad
viral
target
thu
impos
barrier
viru
mutat
escap
rout
mutat
confer
resist
preserv
viru
viabil
rare
peptid
could
extrem
potent
entri
inhibitor
understand
sar
entri
make
multipl
therapeut
target
viral
bind
fusion
feasibl
like
great
valu
certainli
multifacet
approach
sar
entri
inhibit
would
like
succeed
cov
peplom
direct
cell
entri
princip
viral
compon
commun
divers
extracellular
environ
array
extracellular
select
pressur
fix
divers
geneticallyplast
cov
protein
novel
structur
allow
cov
expand
differ
ecolog
nich
zoonot
emerg
sarscov
prime
exampl
emerg
consequ
understand
variat
structur
entri
mechan
therefor
central
combat
potenti
epidem
cov
transmiss
natur
divers
cov
protein
provid
insight
evolut
mechan
cell
entri
exampl
amongst
cov
central
distinct
rbd
trigger
differ
dramat
influenc
pathogen
redirect
cell
tropism
viral
entri
rout
rate
cov
facil
model
correl
variat
cell
entri
diseas
potenti
cov
also
excel
tool
reveal
new
host
cell
compon
facilit
entri
relev
diseas
possibl
speci
organspecif
variat
cov
receptor
sactiv
proteas
one
next
key
step
cov
research
move
toward
vivo
dissect
entri
mediat
relat
diseas
manifest
presenc
abund
distinct
tissu
speci
increasingli
sophist
vivo
cov
model
also
use
evalu
new
antivir
strategi
notabl
infect
model
prototyp
antivir
agent
promis
deliv
therapi
guard
potenti
seriou
zoonot
cov
reveal
antivir
exampl
ttsp
inhibitor
may
suitabl
therapeut
varieti
respiratori
virus
reli
proteolysi
cell
entri
cov
research
continu
reveal
featur
viru
oper
mechan
clinic
applic
antivir
strategi
forese
futur
